SCHEMBL5898762

SCHEMBL5898762

O=C(O)C(c1ccccc1)N1OCC=CC1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.45
GAA P10253 1/20 0.44
ALDH1A1 P00352 5/20 0.42
KDM4E B2RXH2 2/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
XIAP P98170 1/20 0.42
HKDC1 Q2TB90 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CYP2D6 P10635 1/20 0.36
SRC P12931 1/20 0.36
MAPK1 P28482 1/20 0.35
ACE P12821 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
PKM P14618 1/20 0.33
CES2 O00748 1/20 0.33
CES1 P23141 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5898761 1.00 LMNA (0.45) LMNAGAAALDH1A1KDM4EALOX15
SCHEMBL5898773 0.84 ESR1 (0.36) LMNAGAAALDH1A1KDM4EALOX15
SCHEMBL5898774 0.84 ESR1 (0.36) LMNAGAAALDH1A1KDM4EALOX15
SCHEMBL5898778 0.71 RAB9A (0.34)
SCHEMBL5898781 0.71 RAB9A (0.34)
SCHEMBL4957962 0.71 LMNA (0.50) LMNAGAAALDH1A1KDM4EALOX15
SCHEMBL9632134 0.66 LMNA (0.53) LMNAGAAALDH1A1KDM4EALOX15
SCHEMBL9892559 0.66 MGLL (0.42) LMNAGAAALDH1A1MEN1KMT2A
SCHEMBL627906 0.65 ALDH1A1 (0.73) LMNAGAAALDH1A1TSHRHSD17B10
SCHEMBL1706030 0.65 ALDH1A1 (0.73) LMNAGAAALDH1A1TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060069091-A9 Oxazinones and methods for their use and synthesis CHIROLOGIX PHARMACEUTICALS, INC. 2006-03-30 US disclosed
US-20050124612-A1 Oxazinones and methods for their use and synthesis CHIROLOGIX PHARMACEUTICALS, INC. 2005-06-09 US disclosed
US-6861416-B2 Oxazinones and methods for their use and synthesis CHIROLOGIX PHARMACEUTICALS, INC. (CA) 2005-03-01 US disclosed
US-20040023956-A1 New intermediates and synthetic methods for the stereospecific synthesis of oxazinone compounds, which are useful, for example, as antibiotics. The invention also pertains to novel olefinic oxazinone compounds, methods for CHIROLOGIX PHARMACEUTICALS, INC (CA) 2004-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069091-A9 Oxazinones and methods for their use and synthesis DHPS, COASY, SQLE LMNA 4106/4885GAA 901/4885ALDH1A1 584/4885
US-20050124612-A1 Oxazinones and methods for their use and synthesis DHPS, COASY, SQLE LMNA 4106/4885GAA 901/4885ALDH1A1 584/4885
US-20040023956-A1 New intermediates and synthetic methods for the stereospecific synthesis of oxazinone compounds, which are useful, for example, as antibiotics. The invention also pertains to novel olefinic oxazinone compounds, methods for SQLE, DHPS, COASY LMNA 4459/4885GAA 1270/4885ALDH1A1 648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.